Oral RORy nuclear receptor antagonist
on-going Ph. II for psoriasis (QD dosing)
50k cmpd high-conc. frag. screen + scaff. hop
ACS Med. Chem. Lett., Jan. 5, 2021
Boehringer Ingelheim, Ridgefield, CT
BI 730357
1 min read
The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last year in February and March. While most clinical RORγ modulators have discontinued development after reaching Ph. II, BI 730357’s Ph. II trial appears to be on-going.
Search By Structure
- Remogliflozin etabonate
- GLPG2451
- BI 730357
- MLi-2
- “compound 1”
- “compound 5i”
- E7386
- NVS-BET-1
- “compound 16”
- JNJ-63576253
- Dosimertinib
- BMS-986242
- CCS1477
- Con B-1
Molecules of the Month
2023
2022
2021
2020